US Patent 11304953 Combination therapy
Patent 11304953 was granted and assigned to MEI Pharma on April, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Daniel P. Gold0
Edits on 26 Apr, 2023
Golden AI
Edits on 23 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113049530
Date of Patent
April 19, 2022
0Patent Application Number
166136380
Date Filed
May 22, 2018
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 22 Apr, 2023
Golden AI
Edits on 26 Sep, 2022
Golden AI
Edits on 18 May, 2022
Golden AI
Edits made to:
Infobox (+14 properties)
Article (+288 characters)
US Patent 11304953 Combination therapy
Article
Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11304953
Date of patent
April 19, 2022
Patent application number
16613638
Date Filed
May 22, 2018
Patent citations
Patent primary examiner
CPC Code
Find more entities like US Patent 11304953 Combination therapy
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.